Hasta la próxima

Auto reproducción

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1 vistas • 07/09/23
Compartir
Empotrar
administrator
administrator
Suscriptores
0

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Mostrar más
0 Comentarios sort Ordenar por
Comentarios de Facebook

Hasta la próxima

Auto reproducción